Tags

Type your tag names separated by a space and hit enter

24-hour ambulatory blood pressure monitoring and spirapril in mild to severe essential hypertension: a randomized dose comparison.
Blood Press Suppl. 1994; 2:23-30.BP

Abstract

This was a multicentre randomized, double-blind, parallel-group study to compare the antihypertensive efficacy of spirapril at 3 mg with 12 mg once daily, as determined by 24-hour ambulatory blood pressure monitoring (ABPM), in patients with mild to severe essential hypertension. Following a 4-week placebo run-in phase, 52 male and female outpatients, aged 23-67 years with mild to severe essential hypertension [diastolic blood pressure (DBP) > or = 100 mmHg and < 120 mmHg] were randomized to receive spirapril at either 3 mg or 12 mg once daily for 8 weeks. At the end of active treatment and using the standard mercury sphygmomanometer, the number of responders (sitting DBP < 90 mmHg, but decrease > or = 10 mmHg) was the same in both groups (32% and 37%). There were mean decrease in both systolic blood pressure (SBP) and DBP at trough with both 3 mg and 12 mg doses: -9/-7 mmHg and -12/-7 mmHg, respectively. The rate of normalization (trough DBP < or = 90 mmHg) was 12% and 30% with the 3 mg and 12 mg doses, respectively. Of the 44 patients whose daytime ABPM could be compared, one of 20 patients taking 3 mg of spirapril, and 9 of 24 taking 12 mg of spirapril achieved a DBP < or = 90 mmHg for all time intervals while awake. The differences in blood pressure-lowering were significant with both SBP and DBP during the day and at the end of the dosing interval (p < 0.001 and p < 0.01, respectively). The changes from baseline at 24 hours postdose for SBP/DBP were -3/-6 mmHg with 3 mg and -14/-12 mmHg with 12 mg of spirapril.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Department of Internal Medicine, University Hospital, Nijmegen, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8061842

Citation

Vreugdenhil, G, et al. "24-hour Ambulatory Blood Pressure Monitoring and Spirapril in Mild to Severe Essential Hypertension: a Randomized Dose Comparison." Blood Pressure. Supplement, vol. 2, 1994, pp. 23-30.
Vreugdenhil G, van Montfrans GA, Jacobs MC, et al. 24-hour ambulatory blood pressure monitoring and spirapril in mild to severe essential hypertension: a randomized dose comparison. Blood Press Suppl. 1994;2:23-30.
Vreugdenhil, G., van Montfrans, G. A., Jacobs, M. C., de Bruijn, J. H., Veerman, D. P., van Es, P. N., Mellein, B., Guitard, C., Thien, T., & de Leeuw, P. W. (1994). 24-hour ambulatory blood pressure monitoring and spirapril in mild to severe essential hypertension: a randomized dose comparison. Blood Pressure. Supplement, 2, 23-30.
Vreugdenhil G, et al. 24-hour Ambulatory Blood Pressure Monitoring and Spirapril in Mild to Severe Essential Hypertension: a Randomized Dose Comparison. Blood Press Suppl. 1994;2:23-30. PubMed PMID: 8061842.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 24-hour ambulatory blood pressure monitoring and spirapril in mild to severe essential hypertension: a randomized dose comparison. AU - Vreugdenhil,G, AU - van Montfrans,G A, AU - Jacobs,M C, AU - de Bruijn,J H, AU - Veerman,D P, AU - van Es,P N, AU - Mellein,B, AU - Guitard,C, AU - Thien,T, AU - de Leeuw,P W, PY - 1994/1/1/pubmed PY - 1994/1/1/medline PY - 1994/1/1/entrez SP - 23 EP - 30 JF - Blood pressure. Supplement JO - Blood Press Suppl VL - 2 N2 - This was a multicentre randomized, double-blind, parallel-group study to compare the antihypertensive efficacy of spirapril at 3 mg with 12 mg once daily, as determined by 24-hour ambulatory blood pressure monitoring (ABPM), in patients with mild to severe essential hypertension. Following a 4-week placebo run-in phase, 52 male and female outpatients, aged 23-67 years with mild to severe essential hypertension [diastolic blood pressure (DBP) > or = 100 mmHg and < 120 mmHg] were randomized to receive spirapril at either 3 mg or 12 mg once daily for 8 weeks. At the end of active treatment and using the standard mercury sphygmomanometer, the number of responders (sitting DBP < 90 mmHg, but decrease > or = 10 mmHg) was the same in both groups (32% and 37%). There were mean decrease in both systolic blood pressure (SBP) and DBP at trough with both 3 mg and 12 mg doses: -9/-7 mmHg and -12/-7 mmHg, respectively. The rate of normalization (trough DBP < or = 90 mmHg) was 12% and 30% with the 3 mg and 12 mg doses, respectively. Of the 44 patients whose daytime ABPM could be compared, one of 20 patients taking 3 mg of spirapril, and 9 of 24 taking 12 mg of spirapril achieved a DBP < or = 90 mmHg for all time intervals while awake. The differences in blood pressure-lowering were significant with both SBP and DBP during the day and at the end of the dosing interval (p < 0.001 and p < 0.01, respectively). The changes from baseline at 24 hours postdose for SBP/DBP were -3/-6 mmHg with 3 mg and -14/-12 mmHg with 12 mg of spirapril.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0803-8023 UR - https://www.unboundmedicine.com/medline/citation/8061842/24_hour_ambulatory_blood_pressure_monitoring_and_spirapril_in_mild_to_severe_essential_hypertension:_a_randomized_dose_comparison_ L2 - http://www.diseaseinfosearch.org/result/8360 DB - PRIME DP - Unbound Medicine ER -